

# Kenneth J O'byrne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5628142/publications.pdf>

Version: 2024-02-01

352  
papers

37,365  
citations

6613

79  
h-index

3407

183  
g-index

363  
all docs

363  
docs citations

363  
times ranked

36816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	27.0	3,181
2	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3327-3334.	1.6	2,854
3	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 2018, 378, 2093-2104.	27.0	2,469
4	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2019, 381, 2020-2031.	27.0	1,866
5	Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. Journal of Clinical Oncology, 2005, 23, 4265-4274.	1.6	1,435
6	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	10.7	1,369
7	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, The, 2009, 373, 1525-1531.	13.7	1,321
8	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, The, 2016, 17, 577-589.	10.7	950
9	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies. Journal of Clinical Oncology, 2003, 21, 3955-3964.	1.6	648
10	Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncology, The, 2011, 12, 763-772.	10.7	612
11	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2012, 13, 33-42.	10.7	526
12	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Frontiers in Oncology, 2018, 8, 92.	2.8	506
13	Chronic immune activation and inflammation as the cause of malignancy. British Journal of Cancer, 2001, 85, 473-483.	6.4	459
14	First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology, 2019, 37, 992-1000.	1.6	457
15	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 2017, 28, 270-277.	1.2	425
16	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	1.2	410
17	Macrophage and Mast-Cell Invasion of Tumor Cell Islets Confers a Marked Survival Advantage in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8959-8967.	1.6	330
18	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 564601.	3.7	315

#	ARTICLE	IF	CITATIONS
19	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3449-3457.	1.6	311
20	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	1.2	308
21	First-Line Afatinib versus Chemotherapy in Patients with Nonâ€“Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 380-390.	1.1	300
22	Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 1997, 15, 3185-3191.	1.6	292
23	Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With <i>EGFR</i> Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3342-3350.	1.6	285
24	Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. <i>Thorax</i> , 2000, 55, 731-735.	5.6	279
25	Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 473-482.	1.6	262
26	Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2000, 82, 1427-1432.	6.4	252
27	Lipoxygenase metabolism: roles in tumor progression and survival. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 503-524.	5.9	247
28	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2008, 19, 362-369.	1.2	247
29	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	1.2	246
30	The Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 2024-2036.	1.1	243
31	Immune Checkpoint Inhibitors in Cancer Therapy. <i>Current Oncology</i> , 2022, 29, 3044-3060.	2.2	239
32	An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Nonâ€“Small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2006, 12, 1507-1514.	7.0	237
33	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Nonâ€“Small-Cell Lung Cancer: METLung. <i>Journal of Clinical Oncology</i> , 2017, 35, 412-420.	1.6	237
34	Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege. <i>Journal of Clinical Oncology</i> , 2005, 23, 8932-8941.	1.6	233
35	Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy. <i>Frontiers in Oncology</i> , 2013, 3, 120.	2.8	225
36	Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature. <i>PLoS ONE</i> , 2013, 8, e54193.	2.5	221

#	ARTICLE	IF	CITATIONS
37	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	1.2	210
38	Functions and Therapeutic Roles of Exosomes in Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 127.	2.8	210
39	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. <i>Lancet Oncology</i> , The, 2011, 12, 795-805.	10.7	199
40	Nucleophosmin: from structure and function to disease development. <i>BMC Molecular Biology</i> , 2016, 17, 19.	3.0	189
41	Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 623-630.	1.1	188
42	Platinum-based chemotherapy in metastatic breast cancer: current status. <i>Cancer Treatment Reviews</i> , 2004, 30, 53-81.	7.7	184
43	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 2780-2787.	1.6	163
44	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. <i>Annals of Oncology</i> , 2016, 27, 2103-2110.	1.2	159
45	Hypoxia-inducible factor-1 $\alpha$ in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. <i>International Journal of Cancer</i> , 2004, 111, 43-50.	5.1	153
46	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. <i>Lung Cancer</i> , 2012, 76, 19-25.	2.0	153
47	PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. <i>Journal of Pathology</i> , 1996, 179, 80-88.	4.5	144
48	Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. <i>Lung Cancer</i> , 2002, 37, 235-240.	2.0	143
49	Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. <i>Cancer Treatment Reviews</i> , 2014, 40, 445-456.	7.7	143
50	Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer. <i>Annals of Surgery</i> , 2007, 245, 707-716.	4.2	139
51	Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. <i>Microsystems and Nanoengineering</i> , 2019, 5, 8.	7.0	138
52	Lung cancer stem cells: The root of resistance. <i>Cancer Letters</i> , 2016, 372, 147-156.	7.2	130
53	Understanding the tumor microenvironment for effective immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1474-1498.	10.5	130
54	Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 1997, 75, 477-481.	6.4	126

#	ARTICLE	IF	CITATIONS
55	SRL172 (killed <i>Mycobacterium vaccae</i> ) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. <i>Annals of Oncology</i> , 2004, 15, 906-914.	1.2	126
56	18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. <i>British Journal of Cancer</i> , 2006, 95, 1174-1179.	6.4	125
57	Advances in the systemic therapy of malignant pleural mesothelioma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 136-147.	4.3	124
58	The Cancer Stem-Cell Hypothesis: Its Emerging Role in Lung Cancer Biology and Its Relevance for Future Therapy. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1880-1890.	1.1	124
59	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1369-1378.	10.7	124
60	The role of DNA repair pathways in cisplatin resistant lung cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 1161-1170.	7.7	114
61	First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 30-37.	10.7	113
62	Postoperative chemotherapy for nonâ€‘small cell lung cancer: A systematic review and meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 128, 414-419.	0.8	111
63	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 167-175.	0.8	111
64	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology</i> , The, 2020, 21, 1213-1223.	10.7	109
65	Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. <i>British Journal of Cancer</i> , 1998, 77, 1696-1703.	6.4	103
66	Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising. <i>Frontiers in Oncology</i> , 2014, 4, 86.	2.8	100
67	Targeting the fibroblast growth factor receptor family in cancer. <i>Cancer Treatment Reviews</i> , 2016, 46, 51-62.	7.7	99
68	Angiogenesis is an independent prognostic factor in malignant mesothelioma. <i>British Journal of Cancer</i> , 2001, 85, 863-868.	6.4	97
69	Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma *. <i>Chest</i> , 2003, 124, 1916-1923.	0.8	94
70	The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 311.	2.8	94
71	Prognostic value of <i>TP53</i> , <i>KRAS</i> and <i>EGFR</i> mutations in nonsmall cell lung cancer: the EUELC cohort. <i>European Respiratory Journal</i> , 2012, 40, 177-184.	6.7	92
72	The prognostic significance of circulating tumor cells in head and neck and nonâ€‘smallâ€‘cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 5910-5919.	2.8	91

#	ARTICLE	IF	CITATIONS
73	Phospho-Akt Expression Is Associated with a Favorable Outcome in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2930-2936.	7.0	87
74	Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 453-460.	2.3	86
75	Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2800-2821.	3.6	86
76	Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAB) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 500-504.	2.6	85
77	Human single-stranded DNA binding proteins are essential for maintaining genomic stability. <i>BMC Molecular Biology</i> , 2013, 14, 9.	3.0	85
78	Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture. <i>Assay and Drug Development Technologies</i> , 2016, 14, 19-28.	1.2	85
79	Tissue and Blood Biomarkers in Lung Cancer: A Review. <i>Advances in Clinical Chemistry</i> , 2018, 86, 1-21.	3.7	85
80	The emerging role of microRNAs in resistance to lung cancer treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 160-169.	7.7	83
81	Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1626-1635.	1.1	81
82	Interactions Between Hypoxia and Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2006, 7, 250-256.	2.6	80
83	The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1254-1258.	1.1	80
84	Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2003, 98, 542-553.	4.1	79
85	Herceptest: Her2 expression and gene amplification in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2001, 92, 480-483.	5.1	77
86	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017, 116, 175-185.	6.4	76
87	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1784-1791.	1.1	75
88	Gene Expression Analysis of Diagnostic Biopsies Predicts Pathological Response to Neoadjuvant Chemoradiotherapy of Esophageal Cancer. <i>Annals of Surgery</i> , 2009, 250, 729-737.	4.2	71
89	A phase II study of bryostatin 1 in metastatic malignant melanoma. <i>British Journal of Cancer</i> , 1998, 78, 1337-1341.	6.4	70
90	Angiogenesis as a biomarker and target in cancer chemoprevention. <i>Lancet Oncology</i> , The, 2001, 2, 726-732.	10.7	69

#	ARTICLE	IF	CITATIONS
91	Receptor tyrosine kinases and their activation in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 446-461.	3.3	69
92	Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways. <i>Clinical Cancer Research</i> , 2012, 18, 380-391.	7.0	69
93	Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo. <i>BMC Cancer</i> , 2016, 16, 707.	2.6	69
94	Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. <i>Scientific Reports</i> , 2017, 7, 42517.	3.3	69
95	BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. <i>Cancer Letters</i> , 2018, 428, 117-126.	7.2	69
96	Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2009, 4, 869-874.	1.1	68
97	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100.	7.1	68
98	Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2013, 14, 1104-1112.	3.4	66
99	Targeting BRAF mutations in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 1119-1124.	2.8	65
100	A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. <i>British Journal of Cancer</i> , 2002, 87, 15-20.	6.4	64
101	Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 211-218.	2.0	64
102	Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. <i>Molecular Cancer</i> , 2015, 14, 45.	19.2	64
103	Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. <i>British Journal of Cancer</i> , 2003, 88, 1553-1559.	6.4	63
104	The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. <i>Annals of Thoracic Surgery</i> , 2004, 78, 245-252.	1.3	62
105	Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. <i>International Journal of Cancer</i> , 2012, 131, 911-923.	5.1	61
106	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. <i>Oncotarget</i> , 2017, 8, 72544-72563.	1.8	60
107	Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. <i>Clinical Cancer Research</i> , 2002, 8, 1857-62.	7.0	60
108	Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. <i>Cell Death and Disease</i> , 2013, 4, e951-e951.	6.3	59



#	ARTICLE	IF	CITATIONS
109	Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1071-1084.	1.1	59
110	Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. <i>Lancet</i> , The, 1999, 353, 1494-1495.	13.7	58
111	Inflammation and Cancer. <i>Cancer Treatment and Research</i> , 2006, , 1-38.	0.5	58
112	Targeting oxidative stress in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1225-1245.	3.4	58
113	Invading edge vs. inner (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. <i>Journal of Pathology</i> , 2000, 192, 140-149.	4.5	57
114	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). <i>Annals of Oncology</i> , 2006, 17, 1111-1119.	1.2	57
115	Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2013, 8, 930-939.	1.1	56
116	Tumour islet Foxp3 <sup>+</sup> T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2015, 46, 1762-1772.	6.7	56
117	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479.	2.6	56
118	Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). <i>Annals of Oncology</i> , 2015, 26, 1734-1740.	1.2	55
119	Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. , 1997, 74, 565-570.		54
120	Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. <i>PLoS ONE</i> , 2017, 12, e0184922.	2.5	54
121	The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. <i>Thorax</i> , 1999, 54, 169-179.	5.6	53
122	The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2004, 25, 497-501.	1.4	53
123	PIONEER: A Phase III Randomized Trial of Paclitaxel Poliglumex Versus Paclitaxel in Chemotherapy-Naive Women with Advanced-Stage Non-Small-Cell Lung Cancer and Performance Status of 2. <i>Clinical Lung Cancer</i> , 2006, 7, 417-419.	2.6	52
124	Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. <i>Annals of Oncology</i> , 2016, 27, 423-429.	1.2	51
125	Platelet-derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer. , 1997, 181, 196-199.		50
126	Potential of Interferon-?? in Solid Tumours. <i>BioDrugs</i> , 2002, 16, 261-281.	4.6	50



#	ARTICLE	IF	CITATIONS
127	Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2004, 91, 1301-1307.	6.4	50
128	Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1466-1470.	1.1	50
129	Bone matters in lung cancer. <i>Annals of Oncology</i> , 2012, 23, 2215-2222.	1.2	50
130	Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 717-724.	1.1	50
131	Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. <i>Molecular Cancer</i> , 2011, 10, 25.	19.2	49
132	Ipilimumab-induced immune-related renal failure--a case report. <i>Anticancer Research</i> , 2012, 32, 4607-8.	1.1	49
133	bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 545-554.	3.3	48
134	Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. <i>Lung Cancer</i> , 2003, 39, 1-13.	2.0	48
135	Short term <i>ex-vivo</i> expansion of circulating head and neck tumour cells. <i>Oncotarget</i> , 2016, 7, 60101-60109.	1.8	48
136	Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3266-3273.	1.6	46
137	Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2011, 6, e14593.	2.5	44
138	High Coexpression of Both EGFR and IGF1R Correlates With Poor Patient Prognosis in Resected Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 58-66.	2.6	44
139	Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.	2.4	42
140	Targeting histone deacetylases for the treatment of disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 826-852.	3.6	41
141	Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. <i>Cell Death and Differentiation</i> , 2009, 16, 1352-1361.	11.2	40
142	Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage. <i>Nature Communications</i> , 2019, 10, 5501.	12.8	40
143	Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 633305.	3.7	40
144	Chemotherapy induced reversible posterior leukoencephalopathy syndrome. <i>Lung Cancer</i> , 2007, 56, 459-463.	2.0	39

#	ARTICLE	IF	CITATIONS
145	NÄstor-Guillermo Progeria Syndrome: a biochemical insight into Barrier-to-Autointegration Factor 1, alanine 12 threonine mutation. BMC Molecular Biology, 2014, 15, 27.	3.0	38
146	Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue. British Journal of Cancer, 1994, 69, 762-766.	6.4	37
147	Extrapulmonary Small Cell Gastric Carcinoma:<i>A Case Report and Review of the Literature</i>. Acta OncolÃ³gica, 1997, 36, 78-80.	1.8	37
148	Cyclooxygenase-2-Linked Attenuation of Hypoxia-Induced Pulmonary Hypertension and Intravascular Thrombosis. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 51-58.	2.5	37
149	hSSB1 (NABP2/ OBFC2B) is required for the repair of 8-oxo-guanine by the hOGG1-mediated base excision repair pathway. Nucleic Acids Research, 2015, 43, 8817-8829.	14.5	37
150	Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. British Journal of Cancer, 1999, 79, 1413-1418.	6.4	36
151	IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. European Journal of Cancer, 2011, 47, 1908-1918.	2.8	36
152	Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: Lessons from the experience of a high-volume center. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1130-1137.e1.	0.8	36
153	The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e100816.	2.5	36
154	Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 277-288.	1.1	36
155	Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clinical Cancer Research, 2003, 9, 2583-6.	7.0	36
156	Endoscopic papillectomy: a novel approach to difficult cannulation.. Gut, 1996, 39, 36-38.	12.1	35
157	The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 153-166.	7.4	35
158	The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers, 2011, 3, 1426-1453.	3.7	35
159	Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death and Disease, 2012, 3, e449-e449.	6.3	35
160	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35
161	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1. Journal of Clinical Pathology, 2012, 65, 1-7.	2.0	34
162	Estrogen receptor ð² activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis, 2013, 2, e72-e72.	4.9	34

#	ARTICLE	IF	CITATIONS
163	Effects of HER Familyâ€‘targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 807-818.	7.0	34
164	Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. <i>British Journal of Cancer</i> , 1994, 70, 886-892.	6.4	33
165	BRCA1 is an essential mediator of vinorelbineâ€‘induced apoptosis in mesothelioma. <i>Journal of Pathology</i> , 2012, 227, 200-208.	4.5	33
166	COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 49-63.	7.4	33
167	IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 83-90.	2.0	33
168	RanGTPase: A Candidate for Myc-Mediated Cancer Progression. <i>Journal of the National Cancer Institute</i> , 2013, 105, 475-488.	6.3	33
169	Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer. <i>Molecular BioSystems</i> , 2015, 11, 743-752.	2.9	33
170	Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. <i>Cancers</i> , 2019, 11, 380.	3.7	33
171	The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1256.	2.8	33
172	Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2013, 8, e70940.	2.5	33
173	PARP inhibition induces BAX/BAKâ€‘independent synthetic lethality of BRCA1â€‘deficient nonâ€‘small cell lung cancer. <i>Journal of Pathology</i> , 2011, 224, 564-574.	4.5	32
174	A computer image analysis system for microvessel density measurement in solid tumours. <i>Angiogenesis</i> , 2002, 5, 15-20.	7.2	31
175	Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. <i>Gynecologic Oncology</i> , 2004, 94, 502-508.	1.4	31
176	Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. <i>Lung Cancer</i> , 2004, 45, S45-S48.	2.0	31
177	Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. <i>International Journal of Molecular Medicine</i> , 2012, 30, 1505-1511.	4.0	31
178	Prognostic impact of vascular and lymphovascular invasion in early lung cancer. <i>Asian Cardiovascular and Thoracic Annals</i> , 2014, 22, 55-64.	0.5	31
179	Lungscape: Resected Nonâ€‘Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	1.1	31
180	hSSB1 (NABP2/OBFC2B) is regulated by oxidative stress. <i>Scientific Reports</i> , 2016, 6, 27446.	3.3	31

#	ARTICLE	IF	CITATIONS
181	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	2.5	31
182	Potential of Interferon-?? in Solid Tumours. <i>BioDrugs</i> , 2002, 16, 349-372.	4.6	30
183	Expression of Thrombospondin-1 in Resected Colorectal Liver Metastases Predicts Poor Prognosis. <i>Clinical Cancer Research</i> , 2005, 11, 6567-6573.	7.0	30
184	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , 2012, 48, 2983-2992.	2.8	30
185	KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2016, 48, 1290-1296.	3.3	30
186	First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. <i>Journal of Thoracic Oncology</i> , 2021, 16, 665-676.	1.1	30
187	Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 286, L859-L865.	2.9	28
188	Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction. <i>World Journal of Surgery</i> , 2010, 34, 2821-2829.	1.6	28
189	Cisplatin and gemcitabine in the management of metastatic penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 187-190.	1.6	27
190	Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. <i>Cellular Immunology</i> , 2017, 319, 35-42.	3.0	27
191	The MARS feasibility trial: conclusions not supported by data â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 1094-1095.	10.7	26
192	Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2011, 3, 1550-1565.	3.7	26
193	A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution. <i>Nucleic Acids Research</i> , 2016, 44, 7963-7973.	14.5	26
194	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131.	2.0	26
195	High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC). <i>Cancers</i> , 2020, 12, 3551.	3.7	26
196	SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer. <i>Oncotarget</i> , 2016, 7, 72807-72818.	1.8	26
197	A Novel Cyclic Adenosine Monophosphate Analog Induces Hypercalcemia via Production of 1,25-Dihydroxyvitamin D in Patients with Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 4044-4048.	3.6	25
198	Reduced Thrombospondin-1 at Presentation Predicts Disease Progression in Superficial Bladder Cancer. <i>European Urology</i> , 2002, 42, 464-468.	1.9	25

#	ARTICLE	IF	CITATIONS
199	Targeting NF- $\kappa$ B-mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer, 2019, 135, 217-227.	2.0	25
200	Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics. Frontiers in Cell and Developmental Biology, 2021, 9, 801200.	3.7	25
201	Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.. Journal of Clinical Oncology, 1996, 14, 1903-1912.	1.6	24
202	Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1795-1809.	2.8	24
203	Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. European Journal of Cancer, 2009, 45, 3087-3097.	2.8	23
204	Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. Cancer, 2011, 117, 5121-5132.	4.1	23
205	Strategic targeting of the PI3K-NF $\kappa$ B axis in cisplatin-resistant NSCLC. Cancer Biology and Therapy, 2014, 15, 1367-1377.	3.4	23
206	In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. Oncotarget, 2016, 7, 79526-79543.	1.8	23
207	The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies. Clinical and Translational Immunology, 2020, 9, e1215.	3.8	23
208	Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer, 2001, 34, 417-426.	2.0	22
209	Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. Cell Death and Disease, 2016, 7, e2469-e2469.	6.3	22
210	Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. Frontiers in Oncology, 2020, 10, 607349.	2.8	22
211	Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 747-755.	3.8	21
212	Tumor Hypoxia Drives Genomic Instability. Frontiers in Cell and Developmental Biology, 2021, 9, 626229.	3.7	21
213	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient, 2018, 11, 131-141.	2.7	20
214	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2021, 21, 1165-1178.	3.1	20
215	Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC). Frontiers in Oncology, 2021, 11, 798296.	2.8	20
216	Imaging of medullary carcinoma of the thyroid using <sup>111</sup> In-labelled anti-CEA monoclonal antibody fragments. Nuclear Medicine Communications, 1992, 13, 142-148.	1.1	19

#	ARTICLE	IF	CITATIONS
217	Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 111-119.	2.3	19
218	Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 2253-2259.	1.6	19
219	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2019, 11, 548.	3.7	19
220	Malignant Pleural Mesothelioma—An Update. <i>International Journal of Occupational and Environmental Health</i> , 2004, 10, 26-39.	1.2	18
221	Genome Stability Pathways in Head and Neck Cancers. <i>International Journal of Genomics</i> , 2013, 2013, 1-19.	1.6	18
222	Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. <i>European Journal of Cancer</i> , 2017, 83, 302-312.	2.8	18
223	Circulating tumor cell clusters: Insights into tumour dissemination and metastasis. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 1139-1147.	3.1	18
224	Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 685440.	3.5	17
225	The Role of Circulating Biomarkers in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 801269.	2.8	17
226	Imaging of bronchial carcinoid tumours with indium-111 pentetreotide.. <i>Thorax</i> , 1994, 49, 284-286.	5.6	16
227	Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. <i>British Journal of Cancer</i> , 1996, 73, 1161-1165.	6.4	16
228	A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 266-268.	2.3	16
229	In Arrayed Ranks: Array Technology in the Study of Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 411-425.	1.1	16
230	SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18605.	3.3	16
231	Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). <i>Oncology Reports</i> , 2003, 10, 1625-31.	2.6	16
232	Molecular approaches to diagnosis and management of ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 1997, 16, 81-107.	5.9	15
233	A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. <i>Annals of Oncology</i> , 1998, 9, 1205-1211.	1.2	15
234	Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. <i>British Journal of Cancer</i> , 2000, 82, 1759-1763.	6.4	15

#	ARTICLE	IF	CITATIONS
235	Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. <i>Annals of Diagnostic Pathology</i> , 2000, 4, 286-292.	1.3	15
236	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. <i>European Respiratory Journal</i> , 2009, 34, 1477-1486.	6.7	15
237	Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?. <i>Current Diabetes Reviews</i> , 2009, 5, 201-209.	1.3	15
238	IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 162.	2.8	15
239	hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. <i>DNA Repair</i> , 2017, 54, 30-39.	2.8	15
240	Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update. <i>Frontiers in Oncology</i> , 2022, 12, 859152.	2.8	15
241	Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. <i>British Journal of Cancer</i> , 2000, 83, 219-224.	6.4	14
242	The use of microvessel density in assessing human urological tumours. <i>BJU International</i> , 2001, 87, 866-875.	2.5	14
243	Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 367-370.	2.3	14
244	An Extracellular Signal-Regulated Kinase 2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 906-914.	2.9	14
245	The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells. <i>Cells</i> , 2020, 9, 1465.	4.1	14
246	Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8514-8514.	1.6	14
247	MARS: A Sense of Perspective and an Inconvenient Truth. <i>Journal of Thoracic Oncology</i> , 2013, 8, e48-e49.	1.1	13
248	A Rare Case of Omentum Invasive Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, e311-e312.	1.3	13
249	Barrier-to-autointegration-factor (Baf1) modulates DNA double-strand break repair pathway choice via regulation of DNA-dependent kinase (DNA-PK) activity. <i>Nucleic Acids Research</i> , 2021, 49, 3294-3307.	14.5	13
250	Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 591-603.	6.4	13
251	The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 1998, 27, 221-227.	4.4	12
252	Neoadjuvant Crizotinib in Advanced Inflammatory Myofibroblastic Tumour with <i>ALK Gene</i> Rearrangement. <i>Tumori</i> , 2015, 101, e35-e39.	1.1	12



#	ARTICLE	IF	CITATIONS
253	VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach. <i>Epigenomics</i> , 2015, 7, 897-910.	2.1	12
254	How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?. <i>Lung Cancer</i> , 2016, 100, 5-13.	2.0	12
255	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2017, 50, 1044-1052.	3.3	12
256	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. <i>Journal of Translational Medicine</i> , 2020, 18, 99.	4.4	12
257	Spatial profiling technologies and applications for brain cancers. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 323-332.	3.1	12
258	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. <i>Translational Oncology</i> , 2021, 14, 101025.	3.7	12
259	Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. <i>Communications Biology</i> , 2021, 4, 638.	4.4	12
260	The Pandora™s box of novel technologies that may revolutionize lung cancer. <i>Lung Cancer</i> , 2021, 159, 34-41.	2.0	12
261	National Working Group Meeting on ALK diagnostics in lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 11-17.	1.1	11
262	Design, Construction, and Analysis of Cell Line Arrays and Tissue Microarrays for Gene Expression Analysis. <i>Methods in Molecular Biology</i> , 2011, 784, 139-153.	0.9	11
263	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9046-9046.	1.6	11
264	Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. <i>International Journal of Biological Markers</i> , 2004, 19, 262-267.	1.8	11
265	Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9517-9517.	1.6	11
266	A metastatic neuroendocrine anaplastic small cell tumor in a patient with multiple endocrine neoplasia type 1 syndrome. Assessment of disease status and response to doxorubicin, cyclophosphamide, etoposide chemotherapy through scintigraphic imaging with <sup>111</sup> In-pentetreotide. <i>Cancer</i> , 1994, 74, 2374-2378.	4.1	10
267	Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. <i>British Journal of Cancer</i> , 1998, 77, 1950-1956.	6.4	10
268	Evolution, immune response, and cancer. <i>Lancet, The</i> , 2000, 356, 1033-1034.	13.7	10
269	Intramedullary spinal cord metastasis. <i>Lancet Oncology, The</i> , 2001, 2, 607.	10.7	10
270	The Establishment of an ISO Compliant Cancer Biobank for Jordan and its Neighboring Countries Through Knowledge Transfer and Training. <i>Biopreservation and Biobanking</i> , 2014, 12, 3-12.	1.0	10

#	ARTICLE	IF	CITATIONS
271	DNA repair pathways and their therapeutic potential in lung cancer. Lung Cancer Management, 2014, 3, 159-173.	1.5	10
272	hSSB1 associates with and promotes stability of the BLM helicase. BMC Molecular Biology, 2017, 18, 13.	3.0	10
273	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology, 2019, 10, 89.	3.5	10
274	Prior or concurrent radiotherapy and nivolumab immunotherapy in non-“small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 56-62.	1.1	10
275	Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets. Current Medicinal Chemistry, 2020, 27, 1901-1921.	2.4	10
276	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical and Translational Immunology, 2022, 11, .	3.8	10
277	Stimulating immune responses to fight cancer: Basic biology and mechanisms. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 9-15.	1.1	9
278	Novel insight into the composition of human single-stranded DNA-binding protein 1 (hSSB1)-containing protein complexes. BMC Molecular Biology, 2016, 17, 24.	3.0	9
279	Development and characterisation of a panel of phosphatidylinositol 3-kinase “mammalian target of rapamycin inhibitor resistant lung cancer cell lines. Scientific Reports, 2018, 8, 1652.	3.3	9
280	Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 620.	3.7	9
281	Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer. Lung Cancer Management, 2020, 9, LMT38.	1.5	9
282	Digital Holographic Imaging as a Method for Quantitative, Live Cell Imaging of Drug Response to Novel Targeted Cancer Therapies. Methods in Molecular Biology, 2019, 2054, 171-183.	0.9	9
283	Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (Review). Oncology Reports, 0, , .	2.6	9
284	Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma“a phase 3 randomised trial. BMJ Open, 2022, 12, e057663.	1.9	9
285	Chemotherapy for upper gastrointestinal tumours. Postgraduate Medical Journal, 2000, 76, 321-321.	1.8	8
286	Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor. Acta OncolÁgica, 2010, 49, 872-874.	1.8	8
287	A Role for IGF-1R“Targeted Therapies in Small-Cell Lung Cancer?. Clinical Lung Cancer, 2011, 12, 38-42.	2.6	8
288	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 2019, 51, 673-680.	0.6	8

#	ARTICLE	IF	CITATIONS
289	Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. Oxford Medical Case Reports, 2020, 2020, omaa077.	0.4	8
290	COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks. Communications Biology, 2021, 4, 484.	4.4	8
291	The Impact of Rare Human Variants on Barrier-To-Auto-Integration Factor 1 (Banf1) Structure and Function. Frontiers in Cell and Developmental Biology, 2021, 9, 775441.	3.7	8
292	DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. International Journal of Cancer, 2007, 121, 992-998.	5.1	7
293	Transcriptional Regulation of IRS5/DOK4 Expression in Non-Small-Cell Lung Cancer Cells. Clinical Lung Cancer, 2008, 9, 367-374.	2.6	7
294	Fifty years of Sudanese hospital-based obstetric outcomes and an international partnership. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 1608-1616.	2.3	7
295	MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1773-1791.	2.8	7
296	First-line nivolumab+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open, 2022, 7, 100394.	4.5	7
297	A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Annals of Oncology, 1997, 8, 294-296.	1.2	6
298	Assessing support requirements for multidisciplinary team meetings. , 2010, , .		6
299	A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Irish Journal of Medical Science, 2012, 181, 211-214.	1.5	6
300	Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. Scientific Reports, 2016, 6, 18907.	3.3	6
301	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 2016, 12, 1805-1822.	2.4	6
302	Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 615967.	2.8	6
303	Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. Cancers, 2021, 13, 2139.	3.7	6
304	The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer, 2021, 160, 73-77.	2.0	6
305	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8073-8073.	1.6	6
306	hSSB2 (NABP1) is required for the recruitment of RPA during the cellular response to DNA UV damage. Scientific Reports, 2021, 11, 20256.	3.3	6

#	ARTICLE	IF	CITATIONS
307	Pembrolizumab-induced toxic epidermal necrolysis: case report. Oxford Medical Case Reports, 2022, 2022, omac025.	0.4	6
308	Phase I study of the mitomycin C analogue BMS-181174. British Journal of Cancer, 1998, 77, 2020-2027.	6.4	5
309	A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Annals of Oncology, 1999, 10, 981-983.	1.2	5
310	24P CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S65.	1.1	5
311	Clinician Perspective on Molecular Profiling of Non-“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 884-886.	1.6	5
312	EV, Microvesicles/MicroRNAs and Stem Cells in Cancer. Advances in Experimental Medicine and Biology, 2018, 1056, 123-135.	1.6	5
313	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 4651.	3.7	5
314	NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.. Journal of Clinical Oncology, 2017, 35, TPS9097-TPS9097.	1.6	5
315	Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. British Journal of Cancer, 2000, 82, 1776-1782.	6.4	4
316	Familiar drugs may prevent cancer. Postgraduate Medical Journal, 2001, 77, 492-497.	1.8	4
317	A Lung Cancer Responding to Hormonal Therapy. Journal of Thoracic Oncology, 2010, 5, 749-750.	1.1	4
318	Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre. Irish Journal of Medical Science, 2013, 182, 217-225.	1.5	4
319	Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer. NAR Cancer, 2021, 3, zcab022.	3.1	4
320	Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. Heliyon, 2022, 8, e09971.	3.2	4
321	Infection and cancer. Lancet, The, 2001, 358, 156.	13.7	3
322	Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemotherapy and Pharmacology, 2001, 48, 197-201.	2.3	3
323	Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. Molecular and Clinical Oncology, 2015, 3, 1073-1079.	1.0	3
324	Nucleolar caspase-2: Protecting us from DNA damage. Journal of Cell Biology, 2017, 216, 1521-1523.	5.2	3

#	ARTICLE	IF	CITATIONS
325	COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target. Cancers, 2021, 13, 830.	3.7	3
326	Trastuzumab (T) and pertuzumab (P)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines.. Journal of Clinical Oncology, 2014, 32, 643-643.	1.6	3
327	COMMD4 Functions with the Histone H2A-H2B Dimer for the Timely Repair of DNA Double Strand Breaks. SSRN Electronic Journal, 0, , .	0.4	3
328	Management of endocrine resistant breast cancer. The Journal of the British Menopause Society, 2004, 10, 16-23.	1.3	2
329	Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns. Molecular Diagnosis and Therapy, 2014, 18, 1-4.	3.8	2
330	138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). Journal of Thoracic Oncology, 2016, 11, S116-S117.	1.1	2
331	Do ethnic patients report longer lung cancer intervals than Angloâ€Australian patients?: Findings from a prospective, observational cohort study. European Journal of Cancer Care, 2021, 30, e13492.	1.5	2
332	Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC).. Journal of Clinical Oncology, 2017, 35, 11587-11587.	1.6	2
333	Gene Expression Profiling of Human Adipocyte Responses to Insulin and IGF-I Signalling. The Open Diabetes Journal, 2009, 2, 5-17.	0.4	2
334	Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. Frontiers in Immunology, 2022, 13, .	4.8	2
335	Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer. , 2003, 74, 357-374.		1
336	O-78 Microarray analysis of mesothelial cells treated with crocidolite, erionite, IL-1beta and TNF-alpha. Lung Cancer, 2003, 41, S25-S26.	2.0	1
337	Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland. Irish Journal of Medical Science, 2012, 181, 451-452.	1.5	1
338	70P Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response?. Journal of Thoracic Oncology, 2016, 11, S85.	1.1	1
339	OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7. Journal of Thoracic Oncology, 2017, 12, S335-S336.	1.1	1
340	Epigenetic Regulation of Chemokine/Chemokine Receptor Expression. Methods in Molecular Biology, 2013, 1013, 185-201.	0.9	1
341	B2-04: Single agent versus combination therapy in advanced NSCLC patients with performance status 2: Results from a regression analysis of STELLAR 3 and 4. Journal of Thoracic Oncology, 2007, 2, S337-S338.	1.1	1
342	The Prognostic Significance of Circulating Tumour Cells in Head and Neck and Non-Small Cell Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
343	Irish society of gastroenterology. Irish Journal of Medical Science, 1993, 162, 513-528.	1.5	0
344	Irish association for cancer research. Irish Journal of Medical Science, 1994, 163, 341-354.	1.5	0
345	A STEPP too far for FLEX? â€œ Authors' reply. Lancet Oncology, The, 2012, 13, e51.	10.7	0
346	68P Inflammatory mediated mechanisms of cisplatin resistance in non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S84.	1.1	0
347	Convenor's Welcome. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 3-3.	1.1	0
348	74P Elucidating drug resistance mechanisms using 2D and 3D culture systems. Journal of Thoracic Oncology, 2016, 11, S86-S87.	1.1	0
349	Durable complete response to immunotherapy in treatmentâ€resistant metastatic colorectal cancer with thyroid transcription factor 1 expression. ANZ Journal of Surgery, 2020, 90, E97-E99.	0.7	0
350	Identifying driver mutations in squamous cell lung cancer (SCC): The Lung Cancer Genomics Ireland (LCGI) study.. Journal of Clinical Oncology, 2015, 33, 11078-11078.	1.6	0
351	Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 11077-11077.	1.6	0
352	Reducing pre-analytical sample QC failure rates for cancer molecular genetic assays with SLIMamp technology.. Journal of Clinical Oncology, 2022, 40, e15034-e15034.	1.6	0